Left Atrial Improvement in Patients With Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial

Keyphrases

• Heart Failure 100%
• Left Atrial 100%
• Secondary Mitral Regurgitation 100%
• COAPT Trial 100%
• Left Atrial Strain 100%
• Heart Failure Hospitalization 40%
• Edge Repair 40%
• All-cause Mortality 30%
• Heart Failure Patients 30%
• Guideline-directed Medical Therapy 30%
• 6-month Follow-up 30%
• Composite Endpoint 20%
• Functional Mitral Regurgitation 20%
• 24-month Follow-up 20%
• Strain Improvement 20%
• Adverse Effects 10%
• Poor Outcome 10%
• Low Risk 10%
• Left Ventricle 10%
• Mitral Valve 10%
• Multivariable 10%
• Low Dose Rate 10%
• Risk Reduction 10%
• Left Atrial Dilatation 10%
• Outcome Assessment 10%
• Cardiovascular Outcomes 10%
• MitraClip 10%
• Percutaneous Therapy 10%
• Symptomatic Heart Failure 10%
• Left Atrium 10%
• Dichotomous Variables 10%
• Severe Mitral Regurgitation 10%
• COAPT 10%
• Transcatheter Edge-to-edge Repair 10%
• Therapy Groups 10%

Medicine and Dentistry

• Congestive Heart Failure 100%
• Mitral Insufficiency 100%
• Combination Therapy 33%
• All Cause Mortality 11%
• Cardiovascular System 11%
• Mitral Valve 11%
• Left Ventricle 11%
• Arm 11%
• Heart Atrium Enlargement 11%
• Outcome Assessment 11%
• Risk Reduction 11%
• Left Atrium 11%
• Group Therapy 11%
• Adverse Effect 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Congestive Heart Failure 100%
• Mitral Valve Regurgitation 100%
• Combination Therapy 33%
• All Cause Mortality 11%
• Heart Atrium Enlargement 11%